- Home
- BLRX vs GELS Comparison
BLRX vs GELS Comparison
Compare BLRX & GELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- GELS
- Stock Information
- Founded
- BLRX 2003
- GELS 2018
- Country
- BLRX Israel
- GELS Australia
- Employees
- BLRX N/A
- GELS N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- GELS
- Sector
- BLRX Health Care
- GELS
- Exchange
- BLRX Nasdaq
- GELS NYSE
- Market Cap
- BLRX 17.3M
- GELS 19.9M
- IPO Year
- BLRX 2011
- GELS 2024
- Fundamental
- Price
- BLRX $3.59
- GELS $1.92
- Analyst Decision
- BLRX Strong Buy
- GELS
- Analyst Count
- BLRX 2
- GELS 0
- Target Price
- BLRX $220.00
- GELS N/A
- AVG Volume (30 Days)
- BLRX 154.8K
- GELS 51.9K
- Earning Date
- BLRX 03-25-2025
- GELS 02-15-2025
- Dividend Yield
- BLRX N/A
- GELS N/A
- EPS Growth
- BLRX N/A
- GELS N/A
- EPS
- BLRX N/A
- GELS N/A
- Revenue
- BLRX $21,991,000.00
- GELS $95,618.00
- Revenue This Year
- BLRX N/A
- GELS N/A
- Revenue Next Year
- BLRX N/A
- GELS N/A
- P/E Ratio
- BLRX N/A
- GELS N/A
- Revenue Growth
- BLRX N/A
- GELS N/A
- 52 Week Low
- BLRX $3.20
- GELS $1.42
- 52 Week High
- BLRX $57.60
- GELS $5.50
- Technical
- Relative Strength Index (RSI)
- BLRX 36.94
- GELS N/A
- Support Level
- BLRX $3.26
- GELS N/A
- Resistance Level
- BLRX $4.17
- GELS N/A
- Average True Range (ATR)
- BLRX 0.28
- GELS 0.00
- MACD
- BLRX 0.24
- GELS 0.00
- Stochastic Oscillator
- BLRX 36.26
- GELS 0.00
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About GELS GELTEQ LIMITED
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.